Evidence map›Paper›PMID 24350043›Full record

ArticleInternational journal of pharmaceutical investigation2013

Evaluation of in vivo efficacy and toxicity of prednisolone-loaded hydrogel-based drug delivery device.

Amit Kumar De, Plaban Bhattacharya, Sriparna Datta, Arup Mukherjee

Open access · hybridAbstract read
In one paragraph

Article in International journal of pharmaceutical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Amit Kumar DeDepartment of Chemical Technology, Division of Pharmaceutical and Fine Chemical Technology, University College of Science and Technology, University of Calcutta, Kolkata, West Bengal, India.
Plaban BhattacharyaDepartment of Chemical Technology, Division of Pharmaceutical and Fine Chemical Technology, University College of Science and Technology, University of Calcutta, Kolkata, West Bengal, India.
Sriparna DattaDepartment of Chemical Technology, Division of Pharmaceutical and Fine Chemical Technology, University College of Science and Technology, University of Calcutta, Kolkata, West Bengal, India.
Arup MukherjeeDepartment of Chemical Technology, Division of Pharmaceutical and Fine Chemical Technology, University College of Science and Technology, University of Calcutta, Kolkata, West Bengal, India.
University of Calcutta · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drugs prescribed for the treatment of moderate to severe inflammatory bowel disease (IBD) are associated with number of side effects. Targeted drug delivery is essential for the treatment of inflammatory bowel disease in order to increase efficacy and reduce toxicity. The established delivery system is designed on enzyme and time-based release of poorly soluble prednisolone, a drug of choice for the treatment of moderate to severe inflammatory bowel disease. Their pharmacological evaluation was done in 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced model of colitis in rat. The drug was administered once daily for 3 consecutive days. Visible severity of colitis, tissue to bodyweight ratio, tissue histology along with nitric oxide (NO), malondialdehyde (MDA) and myeloperoxidase (MPO) activity of colonic tissue were studied to estimate the efficacy of the drug-loaded delivery system. The highest efficacy was observed for formulation in which Eudragit RS100 (EU) was used along with guar gum (GG) in a ratio 2:5 for the preparation of delivery device. An effective recovery was observed from the study of tissue histology of animals treated with the drug-loaded optimized formulation and the biochemical parameters supported it. The toxicity of prednisolone (PD) was reduced significantly as predicted from thymus to body weight ratio of treated animals. GG and EU RS100 provided a newer bipolymer combination for the colon-targeted delivery of PD which increased its efficacy and reduced the toxic side effects. The in vivo experiments presented effective amelioration from colitis in TNBS-induced animal model of colitis.

Indexed as

Coloneudragit RS100guar gumprednisoloneTNBS colitis

Identifiers

PMID24350043
PMCPMC3853763
OpenAlexW2030205960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.